Squarepoint Ops LLC Has $3.14 Million Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• Squarepoint Ops LLC increased its Charles River Laboratories stake by 959.9% in the second quarter, purchasing 12,555 additional shares for a total position worth approximately $3.14 million. Institutional investors collectively own 98.91% of the company.
• Charles River reported quarterly EPS of $3.02, beating estimates of $2.77, while revenue reached $1 billion but declined 2.7% year over year. The company provided fiscal 2026 EPS guidance of $11.15 to $11.45.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $265.69, below the stock’s reported opening price of $278.02. Insiders sold 165,990 shares worth about $42.6 million over the past quarter.

Squarepoint Ops LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 959.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,863 shares of the medical research company's stock after purchasing an additional 12,555 shares during the quarter. Squarepoint Ops LLC's holdings in Charles River Laboratories International were worth $3,144,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Empirical Finance LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company's stock worth $333,000 after buying an additional 62 shares during the last quarter. Glenmede Trust Co. NA grew its stake in shares of Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company's stock worth $467,000 after acquiring an additional 73 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Charles River Laboratories International by 1.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company's stock valued at $1,260,000 after purchasing an additional 80 shares during the last quarter. Syon Capital LLC raised its stake in Charles River Laboratories International by 2.4% during the 2nd quarter. Syon Capital LLC now owns 3,547 shares of the medical research company's stock valued at $804,000 after purchasing an additional 83 shares during the last quarter. Finally, Advisory Services Network LLC boosted its holdings in Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company's stock valued at $505,000 after purchasing an additional 83 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Victoria Creamer sold 4,179 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares in the company, valued at approximately $7,788,017.16. The trade was a 12.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nancy C. Andrews sold 573 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. The trade was a 28.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 165,990 shares of company stock worth $42,606,388 over the last quarter. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $278.02 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $303.30. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock has a market cap of $13.27 billion, a P/E ratio of -57.32, a PEG ratio of 2.73 and a beta of 1.40. The company's 50-day simple moving average is $260.17 and its 200 day simple moving average is $205.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same quarter last year, the company earned $3.12 earnings per share. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on CRL. CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Barclays reissued an "overweight" rating and set a $300.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Evercore reiterated an "outperform" rating and issued a $320.00 price objective on shares of Charles River Laboratories International in a research report on Friday. Finally, Mizuho set a $264.00 price objective on Charles River Laboratories International in a report on Monday, August 10th. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $265.69.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.